Jazz Pharmaceuticals plc — Director's Dealing 2023

Jun 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2023-06-01

Reporting Person: Patil Neena M (EVP & Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-01	Ordinary Shares	S	1526	$127.9751	Disposed	32900	Direct
2023-06-01	Ordinary Shares	S	74	$128.015	Disposed	32826	Direct

Footnotes

F1: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $127.91 to $128.015. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: Includes 87 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2023.